Skip to main content

Table 1 Demographic and clinical characteristics of 141 colorectal cancer patients

From: Comparison of long-term outcomes between Lynch sydrome and sporadic colorectal cancer: a propensity score matching analysis

Variables LS group
(N = 47)
SCRC group
(N = 94)
χ2 value p value
Age (years)    0.070 0.792
 <  50 35(74.5%) 68(72.3%)   
 ≥50 12(2.5.5%) 26(27.7)   
Gender    0.058 0.810
 Male 26(55.3%) 54(57.4%)   
 Female 21(44.7%) 40(42.6%)   
CEA (ng/ml)    0.104 0.747
 ≥5.2 7(14.9%) 16(17.0%)   
 < 5.2 40(85.1%) 78(83.0%)   
Location    3.177 0.365
 Right colon 18(38.3%) 40(42.6%)   
 Left colon 20(42.6%) 41(43.6%)   
 Rectal 5(10.6%) 11(11.7%)   
 Multiple 4(8.5%) 2(2.1%)   
Tumor size a (cm) 5.17±2.61 5.21±2.79 0.106 0.754
Pathological classification    0.474 0.789
 Adenocarcinoma 34(72.3%) 71(75.5%)   
 Partial mucinous 5(10.7%) 11(11.7%)   
 Mucinous adenocarcinoma 8(17.0%) 12(12.8%)   
Differentiation grade    0.259 0.878
 Well 1(2.1%) 1(1.1%)   
 Moderately 28(59.6%) 56(59.5%)   
 Poorly 18(38.3%) 37(39.4%)   
Cancerous node    0.534 0.465
 Occurrence 2(4.3%) 7(7.4%)   
 Absence 45(95.7%) 87(92.6%)   
Vascular invasion    0.534 0.461
 Occurrence 8(17.0%) 21(22.3%)   
 Absence 39(83.0%) 73(77.7%)   
Perineural invasion    0.252 0.616
 Occurrence 6(12.8%) 15(16.0%)   
 Absence 41(87.2%) 79(84.0%)   
T stage    0.130 0.937
 T1 7(14.9%) 12(12.8%)   
 T2 8(17.0%) 17(18.1%)   
 T3 32(68.1%) 65(69.1%)   
N stage    1.840 0.399
 N0 34(72.3%) 57(60.6%)   
 N1 9(19.1%) 23(24.5%)   
 N2 4(8.6%) 14(14.9%)   
Metastasis    0.265 0.607
 Occurrence 2(4.3%) 6(6.4%)   
 Absence 45(95.7%) 88(93.6%)   
TNM stage    1.200 0.753
 I 13(27.7%) 27(28.7%)   
 II 17(36.2%) 30(31.9%)   
 III 15(31.8%) 31(33.0%)   
 IV 2(4.3%) 6(6.4%)   
KRAS mutant 21(44.6%) 49 (52.1%) 0.695 0.404
NRAS mutant 2(4.3%) 3 (3.2%) 0.104 0.747
Adjuvant chemotherapy    1.420 0.233
 Received 26(55.3%) 42(44.7%)   
  1. CEA Carcinoembryonic antigen, LS Lynch syndrome, SCRC Sporadic colorectal cancer